Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 4, 2015, Pages 441-451

  Lobaton T ^a   Ferrante, M ^a   Rutgeerts, P ^a   Ballet, V ^a   Van Assche, G ^a   Vermeire, S ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

AGE; AGED; ALLERGIC REACTION; ARTICLE; BONE MARROW TOXICITY; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION; INFLAMMATORY BOWEL DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT RISK; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SKIN MANIFESTATION;

EID: 85006489369     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13294     Document Type: Article

References (29)

1. Katz S, Feldstein R. Inflammatory bowel disease of the elderly: a wake-up call. Gastroenterol Hepatol (N Y) 2008; 4: 337–47.
2. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998; 114: 1161–8.
3. Piront P, Louis E, Latour P, Plomteux O, Belaiche J. Epidemiology of inflammatory bowel diseases in the elderly in the province of Liège. Gastroenterol Clin Biol 2002; 26: 157–61.
4. Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol 2011; 106: 1889–97.
5. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785–94.
6. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014; 63: 423–32.
7. Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis 2011; 5: 5–13.
8. del Val JH. Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol 2011; 17: 2734–9.
9. Heresbach D, Alexandre JL, Bretagne JF, et al. Crohn's disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol 2004; 16: 657–64.
10. Ha CY, Katz S. Clinical implications of ageing for the management of IBD. Nat Rev Gastroenterol Hepatol 2014; 11: 128–38.
11. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 16: CD008794.
12. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107: 1409–22.
13. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 30–5.
14. Tofani C, Aberra F, Tierney A, Lichtenstein GR. Infectious complications in IBD patients on immunomodulators, corticosteroids, and anti-TNF therapy: is elderly age a predictor of higher complication rates? Gastroenterology 2013; 144(Suppl. 5): S-113.
15. Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 309–15.
16. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7–27.
17. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965–90.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
19. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–51.
20. Molenberghs G, Verbeke G, Demétrio CG. An extended random-effects approach to modeling repeated, overdispersed count data. Lifetime Data Anal 2007; 13: 513–31.
21. Busquets N, Carmona L, Surís X. Systematic review: safety and efficacy of anti-TNF in elderly patients. Reumatol Clin 2011; 7: 104–12.
22. Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012; 225: 312–9.
23. Müller L, Pawelec G. Aging and immunity – impact of behavioral intervention. Brain Behav Immun 2014; 39: 8–22
24. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210–26.
25. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444–7.
26. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501–8.
27. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617–25.
28. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621–30.
29. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol 2013; 48: 595–600.